Predictive Value of Positron Emission Tomography/Computed Tomography to Assess Early Treatment Response to Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade Without Chemotherapy for HER2-Positive Metastatic Breast Cancer: Are We Ready to Embrace This "Early Metabolic Look" Strategy?

J Clin Oncol. 2015 Aug 20;33(24):2591-3. doi: 10.1200/JCO.2015.62.3082. Epub 2015 Jul 20.

Authors

Komal Jhaveri¹, Gary A Ulaner², Maura N Dickler²

Affiliations

¹ Memorial Sloan Kettering Cancer Center, New York, NY jhaverik@mskcc.org.
² Memorial Sloan Kettering Cancer Center, New York, NY.

PMID: 26195716
DOI: 10.1200/JCO.2015.62.3082

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / diagnostic imaging*
Breast Neoplasms / drug therapy*
Female
Fluorodeoxyglucose F18*
Humans
Radionuclide Imaging

Substances

Fluorodeoxyglucose F18